^
    Back
    Association details:
    Biomarker:BCR-ABL1 Q252H + BCR-ABL1 V299L
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    465 Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Published date:
    11/04/2020
    Excerpt:
    The chemotherapy-free, oral combination of ponatinib, venetoclax and dexamethasone appears safe and has promising early efficacy in this heavily pretreated population of pts with R/R Ph+ ALL...
    Secondary therapy:
    dexamethasone